Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Will this pharma company become a new leader in the weight loss market?

Phase 3 Trials Show Weight Loss for Triple Agonist with OSA Potential

‘We now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea.’ Key takeaways: Retatrutide met primary endpoints in the TRIUMPH-2 and TRIUMPH-3 trials, delivering substantial weight loss at 80 weeks. The clinical data package will support global submissions for the drug as a potential treatment for obesity, knee osteoarthritis pain…